Dual RAS blockade - Unresolved controversy?

Nature Reviews Nephrology

Volumn 9, Issue 11, 2013, Pages 640-

  Makani, Harikrishna ^a   Messerli, Franz H ^a   Bangalore, Sripal ^b   Desouza, Kavit A ^a   Shah, Arpit ^a   Mann, Johannes F E ^c  

^a College of Physicians and Surgeons ^*  (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Munich General Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SPIRONOLACTONE;

CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY FAILURE; LETTER; META ANALYSIS (TOPIC); MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT OUTCOME; DRUG EFFECT; FEMALE; MALE; NOTE;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; MALE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84890804785     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.82-c1     Document Type: Letter

References (14)

1. Ruggenenti, P. & Remuzzi, G. Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment. Nat. Rev. Nephrol. 9, 311-312 (2013).
2. Makani, H., Bangalore, S., Desouza, K.A., Shah, A. & Messerli, F.H. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ 346, f360 (2013).
3. Kunz, R., Friedrich, C., Wolbers, M. & Mann, J.F. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann. Intern. Med. 148, 30-48 (2008).
4. Casas, J.P. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366, 2026-2033 (2005).
5. Parving, H.H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
6. Mann, J.F. et al. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: Results of the ONTARGET trial. J. Hypertens. 31, 414-421 (2013).
7. McMurray, J.J. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors: The CHARM-Added trial. Lancet 362, 767-771 (2003).
8. Pfeffer, M.A. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349, 1893-1906 (2003).
9. Cohn, J.N. & Tognoni, G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667-1675 (2001).
10. Imai, E. et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: A multicentre, randomised, placebo-controlled study. Diabetologia 54, 2978-2986 (2011).
11. Mann, J.F. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
12. Fried, L.F. et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA-NEPHRON D). Clin. J. Am. Soc. Nephrol. 4, 361-368 (2009).
13. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).
14. Juurlink, D.N. et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351, 543-551 (2004).